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Amyloid-b oligomers regulate the properties of human
neural stem cells through GSK-3b signaling
Il-Shin Lee1, Kwangsoo Jung2, Il-Sun Kim1 and Kook In Park1,2
Alzheimer’s disease (AD) is the most common cause of age-related dementia. The neuropathological hallmarks of AD include
extracellular deposition of amyloid-b peptides and neurofibrillary tangles that lead to intracellular hyperphosphorylated tau in
the brain. Soluble amyloid-b oligomers are the primary pathogenic factor leading to cognitive impairment in AD. Neural stem
cells (NSCs) are able to self-renew and give rise to multiple neural cell lineages in both developing and adult central nervous
systems. To explore the relationship between AD-related pathology and the behaviors of NSCs that enable neuroregeneration, a
number of studies have used animal and in vitro models to investigate the role of amyloid-b on NSCs derived from various brain
regions at different developmental stages. However, the Ab effects on NSCs remain poorly understood because of conflicting
results. To investigate the effects of amyloid-b oligomers on human NSCs, we established amyloid precursor protein Swedish
mutant-expressing cells and identified cell-derived amyloid-b oligomers in the culture media. Human NSCs were isolated from
an aborted fetal telencephalon at 13 weeks of gestation and expanded in culture as neurospheres. Human NSCs exposure to
cell-derived amyloid-b oligomers decreased dividing potential resulting from senescence through telomere attrition, impaired
neurogenesis and promoted gliogenesis, and attenuated mobility. These amyloid-b oligomers modulated the proliferation,
differentiation and migration patterns of human NSCs via a glycogen synthase kinase-3b-mediated signaling pathway. These
findings contribute to the development of human NSC-based therapy for AD by elucidating the effects of Ab oligomers on
human NSCs.
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INTRODUCTION
Neural stem cells (NSCs) generated from developing and adult
mammalian brains are defined by their ability to self-renew,
give rise to glial and neuronal cell lineages throughout the
neuraxis and reconstruct developing or damaged central
nervous system regions.1–4 Studies of NSCs isolated from
human fetal brains have advanced clinical approaches
providing replacement and protection of neural cells against
degenerated or injured stimuli5–10 and have facilitated an
increased understanding of human brain development.1
Alzheimer’s disease (AD) is a dire neurodegenerative disease
that frequently occurs in elderly adults. AD neuropathologi-
cally manifests with extracellular deposition of amyloid-b
(Ab), intraneuronal accumulation of hyperphosphorylated
tau and inflammation in the brain. The accompanying
synaptic dysfunction and neuronal loss leads to severe cogni-
tive deficits.11–13 Although the primary cause of AD has not
yet been established, substantial evidence suggests that Ab
cleaved from amyloid precursor protein (APP) by b- and
g-secretase contributes to the development of AD, and soluble
oligomeric species of Ab, rather than Ab plaques, induce
synaptic failure, neuronal toxicity and memory decline in
AD-like animal models.14–16 Interestingly, cell- and AD brain-
derived low-n oligomers of Ab have biologically detrimental
effects on neurons,17–20 even though these oligomers are
smaller than synthetic Ab oligomers.21,22 In addition, Ab
oligomers and peptides activate glycogen synthase kinase-3b
(GSK-3b), whose activity is inversely regulated by the Wnt/b-
catenin signaling pathway23,24 involved in the phosphorylation
of tau22,25 and related to APP processing,26 in AD brains and
rat hippocampal neurons.
A number of previous studies have investigated how NSCs
are modulated in the brains of AD patients by studying diverse
Ab species and using different animal and cell culture models.
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Based on these investigations, each Ab species may play a role
in regulating proliferation, differentiation and migration of
NSCs, although the results of these studies are inconsistent
with reports that Ab either decreases or increases dividing
potential, prevents or induces neurogenesis and inhibits the
movement of NSCs in adult transgenic animals or in vitro.23,27–35
Furthermore, some studies have reported hippocampal
neurogenesis in AD patients.31,36,37 However, neurogenesis in
the dentate gyri of AD patients may be difficult to interpret
because of differences in symptom levels, age and post-
mortem delays in the processing of patient samples. Thus,
the Ab effects on NSCs remain poorly understood.
In the present study, we demonstrate that naturally secreted
Ab oligomers derived from APP Swedish mutant (APPsw)-
expressing cells regulate the proliferation, differentiation and
migration patterns of human fetal brain-derived NSCs via a
GSK-3b-mediated signaling pathway. These findings contri-
bute to the development of human NSC-based therapy for AD
by elucidating the effects of Ab oligomers on the properties of
human NSCs.
MATERIALS AND METHODS
Culture of human NSCs
Human fetal tissue from a cadaver at 13 weeks of gestation was
obtained with full parental consent and approval of the research ethics
committee of Yonsei University College of Medicine, Seoul, Korea. All
procedures conformed to the guidelines of both the National
Institutes of Health and the Korean Government. The freshly
dissected telencephalic tissue was transferred to the Good Manufac-
turing Practice facility, and after dissociation in trypsin (0.1% for
30min, Sigma, St Louis, MO, USA), seeded onto tissue-culture-
treated 100-mm plates (Corning, Tewksbury, MA, USA) at a density
of 400 000 cells per ml in serum-free N2 growth medium, which
consisted of a 1:1 mixture of Dulbecco’s modified Eagle’s medium and
Ham’s F12 (DMEM/F12; Gibco, Grand Island, NY, USA), supple-
mented with 1 penicillin/streptomycin (P/S; Gibco) and N2
formulation (1% v/v; Gibco). Mitogenic stimulation was achieved
by adding 20ngml1 fibroblast growth factor-2 (R&D Systems,
Minneapolis, MN, USA), and 10ngml1 leukemia inhibitory factor
(Sigma). Heparin (8mgml1; Sigma) was added to stabilize fibroblast
growth factor-2 activity. All cultures were maintained in a humidified
incubator at 37 1C and 5% CO2, and half of the growth medium was
replenished every 3–4 days. Proliferating single cells in culture gave
rise to free-floating neurospheres during the first 2–5 days of growth.
Cells were passaged every 7–8 days by dissociation of bulk neuro-
spheres with 0.05% trypsin/EDTA (Gibco).
Viral vector transduction
To express human APP695sw-green fluorescent protein (APPsw-GFP)
and GFP, recombinant lentiviral particles were prepared. The 293T
cells were cultured in DMEM (Gibco) containing 10% fetal bovine
serum (Gibco) and 1 P/S. Subconfluent 293T cells in DMEM were
co-transfected with 20mg pWPI transfer vector containing APPsw-
GFP, 15mg psPAX2 packaging construct and 6mg pMD2G envelope
plasmid by calcium phosphate precipitation. The lentiviral vectors
were kindly donated by the Trono laboratory (Addgene, Cambridge,
MA, USA). After 3 h, fresh DMEM containing 5% fetal bovine serum
and 1 P/S was added. After 2 days, the culture media containing
lentiviral particles were harvested, centrifuged at 3000 r.p.m. for 5min
to remove cell debris and concentrated by ultracentrifugation at
26 000 r.p.m. under a sucrose cushion. The viral titer was determined
as transducing units using flow cytometry, guided by the protocol of
the Trono lab (http://tronolab.epfl.ch/). Lentiviral particles encoding
APPsw-GFP and GFP were respectively transduced into SK-N-MC
cells (human neuroblastoma cells) or human NSCs with a multiplicity
of infection of 1, and these cells were maintained for 1 month and
used for subsequent experiments.
Preparation of conditioned media
SK-N-MC cells untransduced or transduced with lenti-APPsw-GFP or
lenti-GFP were cultured in DMEM containing 10% fetal bovine
serum and 1 P/S. To prepare conditioned media (CM), these cells
were seeded at a density of 6 106 on 100mm culture dishes in 10ml
N2 media and incubated for 3 days. At the end of this period, media
were harvested and cleared by centrifugation at 3000 r.p.m. for 5min.
The CM was divided into aliquots and stored at 70 1C until use.
Neurotoxicity of CM derived from APPsw-expressing
SK-N-MC cells
Three-month-old-C57BL6/J mouse brains were extracted, embedded
in 3% agarose and coronally cut on a vibratome (Motorized Advance
Vibroslice MA752; Campden Instrument, Lafayette, IN, USA) in cold
phosphate-buffered saline (PBS). Four to five 500-mm-thick slices
throughout the cortex were cultured for 1 day and slices incubated in
CM from untransduced SK-N-MC cells (SK-CM), CM from lenti-
GFP-transduced SK-N-MC cells (GFP-CM), CM from lenti-APPsw-
GFP-transduced SK-N-MC cells (APP-CM) and Ab-immunodepleted
or isotype-matched IgG-treated APP-CM. Mouse anti-Ab1-16 (6E10
2mg; Covance, Princeton, NJ, USA) or ChromPure mouse IgG (2mg;
Jackson ImmunoResearch, West Grove, PA, USA) were used for
immunoprecipitation using Dynabeads ProteinG (Invitrogen, Grand
Island, NY, USA) as described below. After 48h, brain slices were
washed with cold PBS, fixed in cold 4% paraformaldehyde (PFA) in
PBS at 4 1C overnight, and subsequently transferred into a 30%
sucrose solution at 4 1C until embedding. The cryoprotected brain
slices in OCT compound (Sakura Finetek, Torrance, CA, USA) were
cut at a thickness of 20mm on slides using a Leica CM1850 cryostat
(Wetzlar, Germany) and stored at 20 1C. The sections were
incubated with freshly prepared permeabilization solution (0.1%
Triton X-100 in 0.1% sodium citrate) for 10min at 4 1C. After
washing with PBS, sections were treated with the terminal deoxynu-
cleotidyl transferase dUTP nick-end labeling (TUNEL) reaction
mixture (a 1:9 mixture of enzyme solutions: label solutions),
processed using an in situ Cell Death Detection Kit (Roche Applied
Science, Mannheim, Germany) for 1 h at 37 1C and washed with PBS.
These sections were blocked with 10% normal donkey serum (Jackson
ImmunoResearch) and 3% bovine serum albumin (BSA; Sigma) in
PBS containing 0.3% Triton X-100 and incubated at 4 1C overnight
with mouse anti-NeuN (1:100; Millipore, Billerica, MA, USA).
Appropriate secondary antibodies conjugated with Dylight 594
(Jackson ImmunoResearch) were applied for 70min at 37 1C followed
by PBS washes, and then mounted with VECTASHIELD Mounting
Medium (Vector, Burlingame, CA, USA). TUNEL-positive and
NeuN-positive cells were observed using an Olympus BX51 micro-
scope (Tokyo, Japan). PC12 cells were cultured in RPMI Media 1640
(Gibco) supplemented with 5% fetal bovine serum, 10% horse serum
(Gibco) and 1 P/S. Single PC12 cells dissociated with 0.05%
trypsin/EDTA were seeded at a density of 5 105 cells per well on
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12-well plates (Corning) in the growth medium. One day later,
culture media were fully replaced with N2 media, SK-CM or APP-
CM, and incubated for 36h. Cell viability was measured using the
Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto,
Japan) according to the manufacturer’s manual. Briefly, at the end
of the incubation, CCK-8 solution was added to each well and
incubated for 3 h at 37 1C. Media harvested from each well were
transferred into a 96-well plate (Corning), and optical density
measured at a wavelength of 450 nm.
Measurement of human NSC proliferation
Cell proliferation was estimated by 50-bromo-20-deoxyuridine (BrdU)
incorporation. Human NSCs were seeded onto six-well plates at a
density of 1 106 cells per well in N2 media to arrest the cell cycle.
Each day, half of the culture media was replaced with CM containing
mitogens and then cultured for 3 days. Neurospheres derived from
these cells were dissociated as single cells, fixed in 70% ethanol,
permeabilized using 2N HCl and labeled with mouse anti-BrdU
antibodies (Sigma) and fluorescein-conjugated anti-mouse IgG anti-
bodies (Vector). The percentage of cells in S phase in the same
samples was determined via propidium iodide staining. BrdU-
immunolabeled cells and DNA content were analyzed by flow
cytometry.
The TUNEL assay was performed using the In Situ Cell Death
Detection Kit. Dissociated single cells mentioned above were fixed
with 4% PFA in PBS for 1 h at room temperature. The samples were
washed with PBS and then permeabilized with 0.1% Triton X-100 in
0.1% sodium citrate buffer for 15min at 4 1C. After 3 washes, cells
were resuspended in TUNEL reaction mixture and incubated for
60min at 37 1C. TUNEL-positive cells were quantified by flow
cytometry, on a BD FACSCalibur (BD Biosciences, San Jose, CA,
USA), reading 10000–20 000 cells per condition. Cell distribution and
staining with each dye were estimated using BD CellQuest, and
images were obtained using either BD CellQuest or FlowJo 9.3.3 (Tree
Star, Ashland, OR, USA).
Senescence-associated b-galactosidase activity assay
As described above, proliferating human NSCs treated with SK-CM
or APP-CM for 3 days were collected, washed and resuspended in
either 0.1M citrate buffer (pH 4.5) or 0.1 M phosphate buffer (pH 6.0).
Cells were lysed by freezing and thawing, and lysates centrifuged at
12 000 g for 7min. The supernatant was mixed with chlorophenol
red-b-D-galactopyranoside (2.2mgml1; Sigma) and 10mM MgCl2. A
heat inactivation control was prepared for 3min at 65 1C. After an
overnight incubation at 37 1C, 1.5 volumes of 1 M Na2CO3 were added
to stop the reaction, each mixed sample was transferred to a 96-well
plate; absorbance at 570 nm was then measured.
Telomere length
Quantitative real-time PCR amplification of the telomere sequence
was performed as described previously.38 The relative telomere length
(telomere (T)/single copy gene (S) ratio) was examined as the ratio of
repeats of telomeres to the single copy gene 36B4, and calculated
using the following formula: telomere length¼ 2(DCp) where
DCp¼CpTelomereCp36B4.39 PCR was performed with 30ng genomic
DNA, SYBR Green master mix (Roche Applied Science) and 200nM
primers in the LightCycler 480 System (Roche Applied Science) as
follows: 95 1C for 2min, 45 cycles of 95 1C for 10 s, 57 1C for 20 s and
72 1C for 60 s in a reaction volume of 20ml in 96-well plates according
to the manufacturer’s protocol. The following primer pairs were used:
50-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-30
and 50-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT-30
for telomeres (200nM); 50-CAGCAAGTGGGAAGGTGTAATCC-30 and
50-CCCATTCTATCATCAACGGGTACAA-30 for 36B4 (300nM).
Immunocytochemistry
A single-cell suspension generated from neurospheres was plated onto
poly-L-lysine (10mgml1; Sigma)-coated eight-well chamber slides
(Nunc, Rochester, NY, USA) in N2 media. Each day, half of the
culture media was replaced with SK-CM or APP-CM. On the sixth
day, cells were fixed with 4% PFA in PBS for 10min and rinsed three
times with PBS. The cells were blocked with 3% BSA and 10% normal
horse serum (Vector) in PBS containing 0.01% or 0.2% Triton X-100
at room temperature for 1 h and then incubated with primary
antibodies: rabbit anti-nestin (1:200; Millipore), rabbit anti-GFAP
(1:1500; DAKO, Glostrup, Denmark), rabbit anti-neuronal class III
b-tubulin (Tuj1, 1:500; Covance), mouse anti-S100b (1:1000; Sigma),
rabbit anti-galactocerebroside (GalC, 1:100; Sigma) and mouse anti-
O4 (1:100; Millipore) at 4 1C overnight. After washing with PBS,
slides were labeled with either fluorescein- or Texas red-conjugated
anti-mouse or rabbit IgG antibodies (1:200; Vector). The percentage
of immunoreactive cells was calculated using images acquired by an
Olympus BX51 microscope. Three to five random fields were selected
for each treatment, and cell ratio counts were performed on fields
counterstained with 40,6-diamidino-2-phenylindole (DAPI; Vector).
Transplantation of human NSCs into NSE/APPsw transgenic
mice
Heterogeneous NSE/APPsw transgenic mice harboring APPsw under
the neuron-specific enolase (NSE) promoter40 were bred with
background-matched C57BL/6J mice. Genotyping PCR was
performed using genomic DNA isolated from newborn mouse tails
at 3–4 weeks of age using the following primer pairs; 50-CTGAGTCT
GCAGTCCTCGA-30 and 50-CTCTTCTCACTGCATGTCTC-30 for NSE-
APPsw, and 50-CTAGGCCACAGAATTGAAAGATCT-30 and 50-GTAG
GTGGAAATTCTACATCATCC-30 as an internal positive control. All
animal studies were performed according to approved protocols of the
institutional animal care and use committee of the Yonsei University
College of Medicine.
A cell suspension of B3.2 105 BrdU-incorporating, lentiviral-
GFP-transduced or untransduced human NSCs in 4ml H-H buffer
(1 Hank’s balanced salt solution, 10mM HEPES, pH 7.4; Invitro-
gen) was administered into the bilateral molecular layer of the dentate
gyrus (A/P, 2.54mm; L, ±2.5mm from bregma; D/V, 2.25mm
from the dura mater) of 13-month-old NSE/APPsw transgenic and
age-matched wild-type mice. Cyclosporine A (10mg kg1) was
intraperitoneally injected daily beginning 1 day before transplanta-
tion. At 6 weeks after transplantation, these mice were transcardially
perfused with cold PBS followed by cold 4% PFA in 0.1M PIPES
buffer (pH 6.9). The brains were carefully extracted, fixed in 4% PFA
in 0.1 M PIPES buffer at 4 1C overnight and subsequently dehydrated
in a 30% sucrose solution at 4 1C overnight. Brains were then
cryoprotected in OCT compound, sectioned to an 18mm thickness
using a freezing cryostat (Leica) and stored at 20 1C. For immu-
nohistochemistry, coronal brain sections were washed twice with PBS,
and then blocked with 10% normal donkey serum and 3% BSA in
PBS containing 0.3% Triton X-100. BrdU staining required a 30-min
pretreatment step in 2N HCl at 37 1C. Primary antibodies were
incubated at 4 1C overnight, appropriate secondary antibodies con-
jugated with either Dylight488 or Dylight594 (Jackson Immuno
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Research) were applied for 70min at 37 1C followed by three PBS
washes and then mounted. The following primary antibodies were
used to identify donor-derived cells: anti-BrdU-fluorescein (1:20;
Roche Applied Science), rabbit anti-GFP (1:200; Invitrogen) and
mouse anti-human cytoplasm (SC121, 1:500; StemCells, Newark, CA,
USA); anti-nestin, Tuj1, glial fibrillary acidic protein (GFAP) and
rabbit anti-olig2 (1:500; Millipore) were used to examine the fate of
grafted human NSCs. Immunolabeled cells were observed and
measured using an Olympus BX51 microscope and a Zeiss LSM
700 confocal microscope (Oberkochen, Germany).
Migration assay
Ten to fifteen neurospheres formed from singly dissociated human
NSCs for 5 days were plated on poly-L-lysine-coated 12-well plates and
maintained in N2 media for 1 day. The culture was refreshed daily
with half SK-CM, GFP-CM or APP-CM for 3 days. To determine the
migration of human NSCs from the neurospheres, cells were fixed on
the fourth day and stained as described above. Areas of DAPI-positive
migrating cells were measured from each neurospheres to the furthest
migrating cell. Alternatively, 2.2 105 SK-N-MC cells transduced or
not transduced with lenti-APPsw-GFP were seeded onto poly-L-lysine-
coated 24-well plates (lower chamber). The bottom of the 3.0-mm
porous insert (upper chamber) of transwell permeable supports
(Corning) was coated with laminin and overlaid onto the plates.
Dissociated human NSCs at a density of 1 105 were added into the
upper chambers. Every day for 3 days, human NSCs that migrated
through the pores and attached under the upper chamber were
counted using DAPI staining. Images were acquired with an Olympus
BX51 microscope and a Zeiss LSM 710 confocal microscope, and
analyzed using the NIH ImageJ software (Bethesda, MD, USA).
Immunodepletion and pharmacological treatments
The 6E10 antibodies (5mgml1) were added to APP-CM for 1 h at
37 1C before treatment, and another sample of APP-CM was
incubated with ChromPure mouse IgG (5mgml1) as an isotype
control under the same conditions. TDZD-8 (Sigma) as an inhibitor
of GSK-3b was used at 12.5mM in CM before treatment. Control
experiments were performed by adding an equal volume of the
dimethyl sulfoxide (DMSO; Sigma) vehicle used to dissolve TDZD-8.
Western blot and enzyme-linked immunosorbent assay
To identify the species of secreted Ab in APP-CM, 20-ml Dynabeads
ProteinG (Invitrogen) were incubated with 2mg mouse monoclonal
anti-6E10 in PBS containing 0.02% Tween-20 at room temperature
for 30min. SK-CM and APP-CM were respectively added to 6E10-
coated Dynabeads and incubated at 4 1C overnight. Sodium dodecyl
sulfate–polyacrylamide gel electrophoresis was then performed with
proteins eluted from the Dynabeads complexes. To assess differences
in secreted APP between SK-CM and APP-CM, CM was concentrated
10-fold using Amicon Ultra-0.5 centrifugal filter devices (Millipore)
in accordance with the manufacturer’s guidelines. These concentrated
CM were resolved by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis as described below.
SK-N-MC cells, lenti-APPsw-GFP or lenti-GFP transduced SK-N-
MC cells and CM-treated human NSCs under the proliferating or
differentiation conditions were lysed with M-PER Mammalian Protein
Extraction Reagent (Thermo, Rockford, IL, USA) supplemented with
Halt Protease and Phosphatase Inhibitor (Thermo). Protein concen-
trations were determined using the Pierce 660 nm Protein Assay
(Thermo) and BSA as a standard. Proteins were resolved on a 4–
15% Mini-PROTEAN TGX gel (Bio-Rad, Hercules, CA, USA) or
16.5% tricine gel41 under reducing conditions, and transferred to a
nitrocellulose membrane. The membrane was incubated in 5% nonfat
milk or 3% BSA in Tris-buffered saline containing 0.1% Tween-20 for
1 h. After an overnight incubation at 4 1C with primary antibodies, the
membrane was washed in Tris-buffered saline containing 0.1% Tween-
20 and incubated at room temperature with peroxidase-conjugated
anti-mouse or rabbit antibodies (Jackson ImmunoResearch) for 1 h.
The following primary antibodies used in a 1:1000 dilution: anti-6E10,
mouse anti-APP (22C11; Millipore), mouse anti-proliferating cell
nuclear antigen (PCNA; Cell Signaling, Danvers, MA, USA), mouse
anti-S100b (Sigma), mouse anti-polysialic acid-NCAM (PSA-NCAM;
Millipore), rabbit anti-myelin basic protein (MBP; Dako), rabbit anti-
b-catenin (Cell Signaling), mouse anti-GSK3b (Santa Cruz
Biotechnology, Dallas, TX, USA), rabbit anti-phospho-GSK3b (Cell
Signaling), rabbit anti-Stat3 (Cell Signaling), rabbit anti-phospho-
Stat3 (Cell Signaling) and b-actin (Sigma). The blots were washed in
Tris-buffered saline containing 0.1% Tween-20, briefly treated with
SuperSignal West Pico Chemiluminescent Substrate (Thermo) and
processed in an LAS 4000 mini (GE Healthcare, Uppsala, Sweden) to
detect immunolabeled bands. The band intensity of proteins of interest
was arbitrarily estimated as a ratio to b-actin using a Multi Gauge V3
(Fujifilm, Tokyo, Japan). The enzyme-linked immunosorbent assay
measurements of Ab40 and Ab42 contained in CM were performed
using the human Ab1-42 (Wako, Osaka, Japan) and Ab1-40
(Immuno-Biological Lab, Gunma, Japan) assay kits according to the
manufacturer’s instructions.
Reverse transcriptase-PCR and real-time PCR
Total RNA was extracted from SK-N-MC cells transduced or
untransduced with lenti-APPsw-GFP or lenti-GFP, and CM-treated
human NSCs under proliferating or differentiation conditions using
TRI Reagent (Molecular Research Center, Cincinnati, OH, USA).
RNA was quantified with a spectrophotometer, and then 1–3mg RNA
was reversely transcribed using SuperScript III Reverse Transcriptase
(Invitrogen) to synthesize cDNAs following the manufacturer’s
protocol. Reverse transcriptase-PCR was performed using 1ml cDNA
as follows: 95 1C for 5min and 27 cycles of 95 1C for 30 s, 57 1C for
30 s and 72 1C for 30 s. Real-time PCR was performed using 1ml
cDNA as follows: 95 1C for 2min and 45 cycles of 95 1C for 15 s and
60 1C for 1min, as mentioned above. Primer sequences are shown in
Supplementary Table 1. The differences in relative gene expression
were normalized with glyceraldehyde 3-phosphate dehydrogenase
expression and evaluated using the Advanced Relative Quantification
based on the E-Method provided by Roche Applied Science.
Oligomeric Ab42 peptides preparation
As described previously,42 synthetic human Ab42 peptides
(Invitrogen) were prepared as soluble oligomers. Briefly, the
peptides were dissolved to 1mM in 1,1,1,3,3,3-hexafluoro
2-propanol (Sigma) and lyophilized. Dried peptides were resolved
to 5mM in DMSO, diluted to 100mM in N2 media and incubated at
4 1C for 24h. In subsequent experiments, these oligomeric peptides
were used at a final concentration of 1mM in culture media. Control
experiments were performed by adding an equal volume of DMSO
used to dissolve dried Ab42.
Statistical analysis
Statistical analyses were performed using the SPSS software (IBM
Company, Armonk, NY, USA). Statistical differences were assessed
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with either the nonparametric Mann–Whitney U-test or the para-
metric unpaired t-test between two groups. Statistical analyses among
at least three groups were performed using the Kruskal–Wallis test
and the Mann–Whitney U-test as a post hoc test. All data are
presented as means±s.e.m. Values of Po0.05 were considered to
indicate significance.
RESULTS
Ab peptides secreted from APPsw-expressing cells exist as
neurotoxic oligomers in CM
A total of 80% of SK-N-MC cells transduced with lenti-
APPsw-GFP exhibited GFP-positive staining, and abundant
expression of APP and Ab (Figures 1a–e). CM derived from
these APPsw-expressing cells (APP-CM) contained higher
levels of Ab40 (37.25±0.36 pgml1, n¼ 3) and Ab42
(1.32±0.01 pgml1) peptides than did CM from GFP-expres-
sing cells (GFP-CM; Ab40, 9.58±0.85 pgml1 and Ab42,
0.26±0.03 pgml1) and SK-N-MC cells (SK-CM; Ab40,
10.08±0.24pgml1 and Ab42, 0.25±0.01pgml1; Figure 1f).
Moreover, Ab proteins secreted from APPsw-expressing cells
remained as monomers and oligomers in CM (Figure 1g).
APP-CM treatment significantly decreased PC12 cell survival
(78.07±1.01% of SK-CM; Figure 2a). In the cortices of brain
slices, APP-CM treatment markedly increased the number of
TUNEL-positive cells (green) in NeuN-positive cells (red)
compared with SK-CM and GFP-CM (Figures 2b–d). Arrows
indicate colocalization of TUNEL- and NeuN-positive cells
(Figure 2d). In contrast, the removal of Ab in APP-CM
Figure 1 Amyloid-b (Ab) peptides secreted from APPsw-expressing cells naturally oligomerize in culture media. (a) Lenti-APPsw-GFP-,
lenti-GFP-transduced and untransduced SK-N-MC cells formed spheres when cultured in N2 media to prepare conditioned media (CM).
(b) Transduced cells markedly expressed GFP only. (c) Flow cytometry analysis showed that 88.5±0.3% of the APPsw-expressing cells
(blue line histogram) and 92.5±0.9% of the GFP-expressing cells (green line histogram) were GFP positive. Untransduced cells were
used as a negative control (black line histogram). (d) Lenti-APPsw-GFP-transduced cells transcribed abundant amyloid precursor protein
(APP), and (e) highly expressed APP and Ab proteins. (f) The quantities of Ab40 and Ab42 in CM were measured by enzyme-linked
immunosorbent assay (ELISA). (g) Ab peptides in CM derived from APPsw-expressing cells were identified as multiple oligomers in blots
probed using the 6E10 antibody after immunoprecipitation with 6E10. Scale bar, 50mm. APP-CM, lentiviral APPsw-GFP-transduced cell-
derived CM; APPsw, amyloid precursor protein Swedish mutant; GFP, green fluorescent protein; GFP-CM, lentiviral GFP-transduced
cell-derived CM; Lt APPsw-GFP, lentiviral APPsw-GFP-transduced cells; Lt GFP, lentiviral GFP-transduced cells; SK-CM, untransduced
cell-derived CM; Untrans, untransduced SK-N-MC cells.
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(APP-CM-6E10) via 6E10 antibody-mediated immunopreci-
pitation did not elicit any neurotoxicity (Figure 2e). As a
control, IgG-immunoprecipitated APP-CM (APP-CM-IgG)
treatment induced colocalization of TUNEL- and NeuN-
positive cells (arrows in Figure 2f). Therefore, Ab peptides
secreted from APPsw-expressing cells are naturally oligomer-
ized in APP-CM, and these Ab oligomers appear to be
markedly neurotoxic.
CM from APPsw-expressing cells reduce proliferation and
induce senescence of human NSCs
Flow cytometry analysis determined that the percentages of
BrdU-positive NSCs after APP-CM and SK-CM treatments
were 25.5±3.7% (n¼ 3) and 46.5±4.3%, respectively
(Figures 3a and b). In addition, the proportion of BrdU-
positive NSCs between SK-CM and GFP-CM treatment had
no difference (Supplementary Figure 1A). Cell cycle distribu-
tion analysis revealed a significant B4% increase in G0/G1-
phase NSCs relative to SK-CM-treated cells after APP-CM
treatment (from 79.3±0.3 to 83.7±0.7%). Concurrently, G1
arrest occurred with a considerable decrease in the proportion
of G2/M and S-phase cells (from 2.4±0.2 to 0.6±0.1% and
from 18.4±0.2 to 15.8±0.8%, respectively; Figure 3d).
However, these CM rarely triggered death of NSCs with either
APP-CM or SK-CM treatments (TUNELþ cellso0.5% of
total cells; Figure 3c). Thus, APP-CM treatment reduced the
dividing potential of human NSCs via cell cycle arrest, but not
via apoptosis. In addition, senescence-associated b-galactosi-
dase activity in extracts of NSCs treated with APP-CM was
markedly increased at pH 4.5 and 6.0 compared with SK-CM
treatment (Figure 3e). The relative telomere length of NSCs
treated with APP-CM was considerably shortened, and telo-
mere reverse transcriptase) expression increased compared
with SK-CM treatment (Figure 3f). Increased telomere reverse
transcriptase levels may reflect an attempt by the cells to
compensate for erosion of telomeres. Therefore, we conclude
that APP-CM treatment induced senescence of NSCs via
telomere dysfunction. These data demonstrate that APP-CM
decreases the proliferation of human NSCs without cell death
and leads to senescence through telomere shortening.
CM from APPsw-expressing cells impair neurogenesis and
promote gliogenesis of human NSCs
Under the differentiation conditions in culture, APP-CM- and
SK-CM-treated NSCs showed the immunoreactivity for the
immature cell marker nestin (32.2±1.3 vs 44.7±2.0%,
Figure 2 APPsw-expressing cell-derived amyloid-b (Ab) oligomers reduce PC12 cell viability and increase the terminal deoxynucleotidyl
transferase dUTP nick-end labeling (TUNEL) positivity of cortical neurons. (a) PC12 cells co-cultured with APP-CM for 36h had 22%
reduced viability compared with cells co-cultured with SK-CM. There was no difference in the cell viability between SK-CM- and GFP-CM-
treated cells. *Po0.05 compared with SK-CM- or GFP-CM-treated cells. (b–f) Representative images of brain slices exhibiting
neurotoxicity from cell-derived Ab oligomers. (b–d) In cortices of brain slices from 3-month-old B57BL6/J mice (n¼8), APP-CM
treatment markedly increased the number of TUNEL-positive cells (green) in NeuN-positive cells (red) compared with SK-CM and
GFP-CM treatment. (e) Ab-immunodepleted APP-CM (APP-CM-6E10) prevented apoptosis of cortical neurons. (f) In contrast, control
IgG-immunoprecipitated APP-CM (APP-CM-IgG) induced colocalization of TUNEL- and NeuN-positive cells. Arrows indicate colocalization
of TUNEL- and NeuN-positive cells. Scale bar, 100mm. APP-CM, lentiviral APPsw-GFP-transduced cell-derived CM; APPsw, amyloid
precursor protein Swedish mutant; CM, conditioned media; GFP, green fluorescent protein; GFP-CM, lentiviral GFP-transduced cell-derived
CM; SK-CM, untransduced cell-derived CM.
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respectively, n¼ 3), early neuronal marker Tuj1 (40.7±0.9 vs
48.1±0.5%), astrocyte markers GFAP (67.5±1.6 vs
59.9±1.8%) and S100b (18.1±1.9 vs 11.5±2.2%) and
oligodendrocyte precursor markers GalC (50.2±2.6 vs
31.6±2.2%) and O4 (40.1±3.5 vs 23.6±2.5%; Figures 4a–g).
Intriguingly, a few nestin-positive cells coexpressed Tuj1, GFAP
and GalC. Although cell fate is driven toward a neuronal
or glial lineage, these colabeled cells may remain in an
immature state. However, these findings indicate that APP-
CM treatment induces the differentiation of NSCs into
astrocytes or oligodendrocytes rather than neurons as com-
pared with SK-CM treatment. In addition, quantitative PCR
Figure 3 Conditioned media (CM) derived from APPsw-expressing cells reduce proliferation, induce senescence and promote telomere
shortening of human neural stem cells (NSCs). (a, b) Representative histograms of flow cytometry analysis. (a) The percentages of
50-bromo-20-deoxyuridine (BrdU)-positive NSCs in total cells were calculated following APP-CM (green line) and SK-CM (blue line)
treatments. A negative control (red line) was included without primary BrdU antibodies. (b) The percentage of BrdU-positive cells after
APP-CM treatment was significantly smaller than that after SK-CM treatment. (c) In both APP-CM and SK-CM treatments, few NSCs were
positive for terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL; o0.5% of total cells). (d) Cell cycle distribution of
human NSCs using flow cytometry. After APP-CM treatment, NSCs in G0/G1 significantly increased by B4% relative to SK-CM-treated
cells. Concurrently, G1 arrest occurred with a considerable decrease in the proportion of G2/M- and S-phase cells. (e) Senescence-
associated b-galactosidase (SA b-gal) activity in human NSCs. APP-CM treatment significantly induced an increase in SA b-gal activity at
both pH 6.0 and 4.5 compared with SK-CM treatment. (f) Relative telomere length and telomere reverse transcriptase (TERT) expression
in human NSCs using real-time PCR. APP-CM treatment induced lower telomere length and higher expression of TERT in NSCs than
SK-CM treatment. Mann–Whitney U-test, *Po0.05. APP-CM, lentiviral APPsw-GFP-transduced cell-derived CM; APPsw, amyloid
precursor protein Swedish mutant; CM, conditioned media; GFP, green fluorescent protein; SK-CM, untransduced cell-derived CM.
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analysis determined that APP-CM treatment elicited signifi-
cantly increased levels of GFAP and GalC, and decreased levels
of nestin and Tuj1 in NSCs, as compared with SK-CM
treatment (Figure 4h). In addition, there was no difference
of fate of NSCs between the treatment of GFP-CM and SK-CM
(Supplementary Figure 1B). Thus, the results suggest that
APP-CM stimulates the differentiation of human NSCs, and
enhances the glial cell fate, while abrogating neuronal fate
of NSCs.
Following transplantation of human NSCs into NSE/APPsw
transgenic mice brains, GFP- or BrdU-positive grafted cells
migrated and engrafted into the dentate gyrus of the
hippocampus at 6 weeks after grafting (Figures 5a and b).
BrdU-positive cells were fully colocalized with SC121, a
human-specific cytoplasm marker (Figure 5c), and gave rise
to multiple neural cell lineages in both NSE/APPsw transgenic
and wild-type mice brains (Figures 5d, e and g–i).
In particular, counting of GFAP-positive cells among
Figure 4 Conditioned media (CM) derived from APPsw-expressing cells reduce neurogenesis and promote gliogenesis of human neural
stem cells (NSCs). (a–g) Representative images of differentiated NSCs in vitro. APP-CM treatment significantly altered the percentages of
cells positive for nestin (red in (a)), class III b-tubulin (Tuj1; green in (b)), glial fibrillary acidic protein (GFAP; green in (c)), S100b
(red in (d)), galactocerebroside (GalC; green in (e)) and O4 (red in (f)) in total 4’,6-diamidino-2-phenylindole (DAPI)-positive cells (blue)
compared with SK-CM treatment. APP-CM treatment induced the differentiation of NSCs into more astrocytes (c, d) and oligodendrocytes
(e, f) rather than neurons (b). (h) Relative expression of cell markers in NSCs treated with APP-CM and SK-CM using real-time PCR.
APP-CM treatment induced significant decreases in nestin and Tuj1, and increased levels of GFAP and GalC in NSCs compared with SK-
CM treatment. Mann–Whitney U-test, *Po0.05. APP-CM, lentiviral APPsw-GFP-transduced cell-derived CM; APPsw, amyloid precursor
protein Swedish mutant; CM, conditioned media; GFP, green fluorescent protein; SK-CM, untransduced cell-derived CM.
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BrdU-positive cells showed a significant 10% increase in NSE/
APPsw transgenic mice compared with age-matched wild-type
mice (Figure 5f). Therefore, these results indicate that the Ab-
enriched milieu in NSE/APPsw transgenic mice brains may
enhance astroglial differentiation of transplanted human
NSCs, consistent with the in vitro results.
Ab oligomers secreted from APPsw-expressing cells
modulate proliferation and differentiation of human NSCs
via GSK-3b activation
APP-CM treatment significantly reduced the expression of
PCNA in NSCs under the proliferation conditions. However,
Ab-immunodepleted APP-CM (APP-CM-6E10) restored the
level of PCNA (Figures 6a and c). In NSCs under the
differentiation conditions, the expression of PSA-NCAM,
S100b and MBP induced by APP-CM treatment was also
inversely regulated by Ab-depleted APP-CM (Figures 6b
and c). Thus, Ab oligomers in APP-CM play a key role in
modulating NSCs under both proliferation and differentiation
conditions. To investigate the mechanism mediating the effect
of Ab oligomers in APP-CM on NSCs, NSCs were treated with
both APP-CM and APP-CM containing TDZD-8 (APP-CM-
TDZD-8). APP-CM treatment significantly decreased phos-
phorylation of GSK-3b at Ser9, an inactive form of GSK-3b
(Figures 6d and e). Sequentially, activated GSK-3b reduced the
level of b-catenin, a GSK-3b-targeted downstream molecule
(Figures 6d and e). However, APP-CM-TDZD-8 treatment
restored the levels of PCNA, PSA-NCAM, S100b and MBP, as
Figure 5 Enhanced astroglial differentiation of human neural stem cells (NSCs) in NSE/APPsw transgenic mice following transplantation.
APPsw, amyloid precursor protein Swedish mutant; NSE, neuron-specific enolase. (a–c) Representative images of graft-derived cells.
Green fluorescent protein (GFP; green in (a))- or 50-bromo-20-deoxyuridine (BrdU; green in (b))-positive transplanted cells showed robust
migration and engraftment in the dentate gyrus of the hippocampus at 6 weeks after grafting. (c) BrdU-positive cells (green) were
colocalized with human-specific cell marker SC121 (red). (d, e) Confocal microscopic images showed that some of the BrdU-positive cells
(arrowheads, green) were colocalized with glial fibrillary acidic protein (GFAP)-positive cells (red) in the dentate gyri of both NSE/APPsw
and age-matched wild-type mice. (f) Numbers of GFAP-positive cells among BrdU-positive grafted cells were significantly increased (by
10%) in NSE/APPsw transgenic mice (n¼4) compared with age-matched wild-type mice (n¼3). Mann–Whitney U-test, *Po0.05. (g–i)
Transplanted human NSCs gave rise to all three neural cell types: neurons, oligodendrocytes and astrocytes in mouse brains. BrdU-
positive cells (green) expressed class III b-tubulin (Tuj1; red) in wild-type mice (g) and nestin (red) in transgenic mice (i). Grafted SC121-
positive cells (green) expressed olig2 (red) in transgenic mice (h). Scale bar, 100mm in (a, b); 20mm in (c–e, g–i).
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well as GSK-3b phosphorylation and b-catenin, to that
expressed after SK-CM treatment (Figures 6d and e). Thus,
these data suggest that Ab oligomers secreted from APPsw-
expressing cells decrease proliferation, impair neurogenesis and
promote gliogenesis of human NSCs in a GSK-3b-dependent
manner. In addition, Stat3 (signal transducer and activator of
transcription 3) phosphorylation of NSCs under differentia-
tion conditions was observed after APP-CM treatment, which
was inversely regulated by APP-CM-TDZD-8 treatment
(Figure 6e). The phosphorylation of Stat3 is known to be
involved in the gliogenesis of NSCs.43,44
Ab oligomers secreted from APPsw-expressing cells
attenuate the migration of human NSCs via GSK-3b
activation
Human NSC-derived neurospheres exposed to APP-CM and
SK-CM migrated radially out of the spheres, and these cells
expressed nestin, Tuj1 and GFAP (Figures 7A–D). The area of
Figure 6 Amyloid-b (Ab) oligomers in conditioned media (CM) derived from APPsw-expressing cells regulate the proliferation and
differentiation of human neural stem cells (NSCs) via a glycogen synthase kinase-3b (GSK-3b)-mediated signaling pathway. (a, b) Western
blot analysis of human NSCs. (a) In comparison with SK-CM treatment, the proliferating cell nuclear antigen (PCNA) level of NSCs under
proliferative conditions was decreased by APP-CM treatment, which was restored by treatment with Ab-neutralized APP-CM (APP-CM-
6E10). IgG-immunoprecipitated APP-CM (APP-CM-mIgG) treatment was used as a control. (b) In NSCs under differentiation conditions,
APP-CM treatment decreased the level of PSA-NCAM, and increased the levels of S100b and myelin basic protein (MBP) compared with
SK-CM treatment. However, the levels of PSA-NCAM, S100b and MBP induced by APP-CM were inversely regulated by APP-CM-6E10.
(c) Relative protein levels of PCNA, PSA-NCAM, S100b and MBP in NSCs treated with SK-CM, APP-CM and APP-CM-6E10. Mann–
Whitney U-test, *Po0.05 vs SK-CM; #Po0.05 vs APP-CM; wPo0.05 vs APP-CM-6E10. (d) Under proliferative conditions, the levels of
PCNA, GSK-3b phosphorylation (pGSK-3b) and b-catenin of NSCs were decreased by APP-CM treatment, and inversely regulated by
treatment with APP-CM containing TDZD-8, an inhibitor of GSK-3b (APP-CM-TDZD-8). APP-CM containing DMSO (APP-CM-DMSO) was
used as a control. The bars show the relative protein levels of PCNA, pGSK-3b and b-catenin (right panel). Mann–Whitney U-test,
*Po0.05 vs SK-CM; #Po0.05 vs APP-CM; wwPo0.05 vs APP-CM-TDZD-8. (e) In NSCs under differentiation conditions, APP-CM
treatment decreased the level of PSA-NCAM, pGSK-3b and b-catenin, and increased the levels of S100b, MBP and signal transducer and
activator of transcription 3 (Stat3) phosphorylation (pStat3) compared with SK-CM treatment. The protein levels induced by APP-CM were
inversely regulated by APP-CM-TDZD-8. The bars show the relative protein levels (right panel). Mann–Whitney U-test, *Po0.05 vs
SK-CM; #Po0.05 vs APP-CM; wwPo0.05 vs APP-CM-TDZD-8. APP-CM, lentiviral APPsw-GFP-transduced cell-derived CM; APPsw, amyloid
precursor protein Swedish mutant; DMSO, dimethyl sulfoxide; GFP, green fluorescent protein; SK-CM, untransduced cell-derived CM.
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migrating cells from the neurospheres was significantly
decreased after APP-CM treatment (0.14±0.01mm2, n¼ 10)
compared with SK-CM treatment (0.23±0.02mm2) (Figures
7Aa, Bb and E). In addition, there appeared to be no difference
in the extent of cell migration from the neurospheres between
GFP-CM and SK-CM treatment (Supplementary Figure 1C).
Thus, APP-CM treatment inhibited the distribution of migrat-
ing cells from the edge of the neurosphere, and attenuated the
migratory potential of human NSCs. In addition, when NSCs
were co-cultured with APPsw-expressing cells in transwells
for 3 days, the number of NSCs that migrated across
the membrane was significantly decreased compared with
Figure 7 Amyloid-b (Ab) oligomers in conditioned media (CM) derived from APPsw-expressing cells inhibit the migration of human neural
stem cells (NSCs). (A–E, Aa, Bb) The migration of NSCs from neurospheres. Many of the nestin-, class III b-tubulin (Tuj1)- or glial
fibrillary acidic protein (GFAP)-positive cellular processes of NSCs were migrating away from the neurosphere in SK-CM, whereas APP-CM
treatment inhibited cellular migration from the neurosphere (A–D). When areas of migrating cells from neurosphere were calculated (Aa,
Bb), APP-CM treatment significantly decreased cellular migrating areas compared with SK-CM (E). Unpaired t-test, *Po0.05. Scale bar,
100mm. (F–H) The movement of NSCs across the membrane of transwells when co-cultured with APPsw-expressing and untransduced
SK-N-MC cells in transwells for 3 days. Representative images of migrating 40,6-diamidino-2-phenylindole (DAPI)-positive NSCs on the
bottom of the membrane at the third day after co-culture (F, G). Compared with SK-N-MC cells, co-culture with APPsw-expressing cells
significantly reduced the number of NSCs across the membrane for 3 days (214.6±21.8 vs 180.3±2.9 on the first day, 560.4±12.5
vs 291.6±37.3 on the second day and 884.3±42.4 vs 481.3±41.9 on the third day, respectively) (H). Mann–Whitney U-test,
*Po0.05. Scale bar, 100mm. (I–J) Ab oligomers attenuated the migration of NSCs in a glycogen synthase kinase-3b (GSK-3b)-
dependent manner. Ab oligomers in CM derived from APPsw-expressing cells (APP-CM) markedly reduced cellular migration from
neurosphere, whereas the removal of Ab peptides in APP-CM by 6E10 antibody-mediated immunoprecipitation (APP-CM-6E10) restored
the migratory capacity of NSCs (I, J). However, isotype-matched IgG treated APP-CM (APP-CM-IgG) as a control did not influence
migration of NSCs (L). GSK-3b inactivation in APP-CM triggered by TDZD-8 increased mobility of NSCs (K). Scale bar, 50mm. APP-CM,
lentiviral APPsw-GFP-transduced cell-derived CM; APPsw, amyloid precursor protein Swedish mutant; GFP, green fluorescent protein;
SK-CM, untransduced cell-derived CM.
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co-culture with SK-N-MC cells on the first, second and third
day, respectively (Figures 7F–H). This result suggests that Ab
released from APPsw-expressing cells may reduce the mobility
of NSCs through the pores of the membrane. Furthermore, by
using 6E10 antibody-mediated immunoprecipitation, the
removal of Ab peptides in APP-CM restored the migratory
capacity of NSCs out of neurospheres, whereas APP-CM-IgG
treatment as a control did not affect migration (Figures 7I, J
and L). GSK-3b inactivation in APP-CM by TDZD-8 also
increased mobility of NSCs (Figure 7K). Therefore, Ab
oligomers secreted from APPsw-expressing cells attenuated
the migration of human NSCs via GSK-3b activation.
Oligomeric forms of synthetic Ab42 peptides modulate the
proliferation, differentiation and migration patterns of
human NSCs
Rather than investigating the naturally secreted Ab oligomers
from SK-N-MC cells, we examined the effects of synthetic
Ab42 peptides prepared as oligomers on the properties of
NSCs. Under the same conditions described above, we
evaluated the proliferation, differentiation and migration
patterns of NSCs. After treatment with 1mM of synthetic
Ab42 oligomers, NSCs under proliferative conditions showed
B50% decrease of BrdU-positive cells relative to normal N2
media or DMSO treatment as controls (Figure 8a). Treatment
with synthetic Ab oligomers induced a significant decrease in
nestin and Tuj1, and increase in GFAP and GalC, gene
expression in NSCs under differentiation conditions compared
with N2 media and DMSO treatment as controls (Figure 8b).
Finally, the distribution of NSCs from neurospheres was
markedly decreased by synthetic Ab42 oligomers compared
with treatment with N2 media and DMSO (Normal,
0.30±0.04mm2, n¼ 5; DMSO, 0.26±0.01mm2; Ab42,
0.14±0.02mm2; Figures 8c–f). Thus, synthetic Ab42 oligo-
mers decrease the proliferation, promote the gliogenesis and
suppress the migration of NSCs, which is consistent with the
finding that Ab oligomers in APP-CM have a marked effect on
the properties of human NSCs.
DISCUSSION
In this study, we examined the functional impact of cell-
derived naturally secreted Ab oligomers on the properties of
NSCs isolated from human fetal telencephalon. Ab derived
from APPsw-expressing cells maintained an oligomeric as well
as a monomeric state in culture media and elicited neurotoxi-
city, similar to previous reports.16,45,46 Accumulating evidence
suggests that soluble Ab oligomers strongly correlate with the
cognitive decline of AD patients and may be a key toxic
molecule in AD.47,48 However, Ab oligomers aggregated from
synthetic Ab monomers are unlikely to recapitulate the
conformation of naturally aggregated Ab oligomers through
post-translational modification.21,22 Therefore, biologically
aggregated Ab oligomers in CM derived from APPsw-
expressing cells may be a reasonable model for investigation
Figure 8 Synthetic amyloid-b (Ab) oligomers regulate the proliferation, differentiation and migration of human neural stem cells (NSCs)
similar to cell-derived Ab oligomers. (a) The number of 50-bromo-20-deoxyuridine (BrdU)-incorporating NSCs was reduced significantly
after synthetic Ab oligomer treatment. (b) Synthetic Ab oligomers induced a significant decrease in nestin and class III b-tubulin (Tuj1),
and an increase in glial fibrillary acidic protein (GFAP) and galactocerebroside (GalC), gene expression. (c–e) Radial migration of NSCs
from neurospheres was impaired by treatment with synthetic Ab oligomers. Scale bar, 100mm. (f) Synthetic Ab oligomers significantly
decreased cellular migrating areas from neurospheres compared with normal N2 media or dimethyl sulfoxide (DMSO) treatment.
Mann–Whitney U-test, *Po0.05.
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of the Ab-related effect on NSCs. Human NSCs used in the
present study were isolated from a fetal telencephalon at 13
weeks of gestation and expanded in culture as neurospheres.
They were able to self-renew, differentiate into multiple neural
cell types and integrate into the host neural circuitry after
transplantation into the developing and adult central nervous
system.49,50 Herein, we demonstrate that Ab oligomers derived
from APPsw-expressing cells reduced the proliferation and
neuronal differentiation, enhanced the glial differentiation and
attenuated the migration of human NSCs in a GSK-3b-
dependent manner. In addition, synthetic Ab42 oligomers
regulate the properties of human NSCs identically to cell-
derived Ab oligomers, and human NSCs grafted into the
brains of APPsw transgenic mice exhibited increased astroglial
differentiation.
AD brain samples and chondroitin sulfate proteoglycan
NG2-positive neural progenitors from cortical tissue of AD
patients exhibit high levels of GSK-3b.23,51 Our results
showed that Ab oligomers in APP-CM activated GSK-3b in
human NSCs. Activated GSK-3b stimulated the degradation
of b-catenin in human NSCs under proliferative conditions.
As stabilization of b-catenin in embryonic mouse brain
maintains the division of cortical progenitors resulting from
an increased mitotic rate,52 relatively low levels of b-catenin
may inversely regulate the proliferation of human NSCs via
cell cycle exit. In addition, Ab oligomers accelerated telomere
shortening and senescence, supporting reports that Ab
peptides induced senescence of endothelial and peripheral
blood mononuclear cells from AD patients with excessive
telomere loss,53,54 resulting in an abrogation of cell
proliferation.55 Interestingly, the death of human NSCs was
negligibly induced by Ab oligomers in this study. NSCs
constitutively generate various neurotrophins against
apoptosis and rarely express glutamate or voltage-gated ion
channels that contribute to glutamate toxicity. Thus, Ab
oligomers may not trigger apoptosis of human NSCs because
of autonomously secreted neurotrophins, unlike previous
findings for neurons.45,56
Currently, it is difficult to determine alterations in
hippocampal neurogenesis in AD animal models because of
differences among mouse strains, diverse APP mutant-
derived Ab contents or age variations.27,29,30,35 Moreover,
these differences may allow Ab toxicity to induce neuronal
dysfunction and inflammation, which could stimulate or
impair neurogenesis and promote the migratory potential of
NSCs toward inflamed lesions in animal brains.57–59 Under
differentiation conditions, our results are consistent with
previous reports that Ab peptides impair neurogenesis of
fetal telencephalon-derived human NSCs.29,32 In contrast,
Ab42 peptides promote neurogenesis of mouse hippocampal
NSCs, and the fates of rat cortical NSCs were differentially
regulated by Ab40 and 42.28,34 These inconsistencies may
result from species differences and variations among NSCs
isolated from different anatomical regions. Indeed, NSCs
from distinct spatiotemporal neural tissue show different
behaviors, ranging from molecular mechanism to fate
determination.2,3,60 As described above, human NSCs
exposed to Ab oligomers showed decreased b-catenin levels
by activated GSK-3b under differentiation conditions.
Previous studies indicated that the Wnt/b-catenin signaling
pathway regulates neuronal differentiation in cortical NSCs,
the embryonic cortex and the adult hippocampus.61–63
Moreover, Ab peptides directly inhibit the Wnt/b-catenin
signaling pathway through interaction with the Frizzled
family of Wnt receptors in 293T cells or the induction of
Dickkopf-1, a negative regulator of Wnt signaling, in cortical
neurons and AD brains.24,64 Thus, human NSCs treated with
Ab oligomers impair neurogenesis because of decreased
b-catenin levels induced by activated GSK-3b, similar to
NG2-positive neural progenitors from AD patients.23
Interestingly, Ab oligomers increased the phosphorylation
of Stat3, which modulates gliogenesis of NSCs via the Janus
kinase/STAT signaling pathway.43,44 Although interactions
between Stat3 and GSK-3b are not directly defined in
NSCs,65,66 the inhibition of GSK-3b reduced the phos-
phorylated Stat3 level and gliogenesis of human NSCs
cultured with Ab oligomers in this study. In addition, the
increased phosphorylation of Stat3 associated with neuronal
death was recently reported in APP751SL/PS1M146L
transgenic mice brains, in cortical neurons treated with Ab
and in the hippocampi of AD patients.67 However, we cannot
explain how the interactions between Stat3 and GSK-3b are
involved in Ab oligomer-related gliogenesis of human NSCs
in this study. Taken together, these findings provide
convincing evidence that cell-derived Ab oligomers inhibit
neurogenesis of human NSCs by blocking the b-catenin
signaling pathway through the activation of GSK-3b. Cell-
derived Ab oligomers also enhanced gliogenesis of human
NSCs through the activation of GSK-3b and/or Stat3
signaling. Consistent with other studies that indicate that
Ab peptides impair the migration of NSCs cultured as
neurospheres,29,32 we show that cell-derived Ab oligomers
suppressed the migration of human NSCs via the GSK-3b
signaling. In addition, another study reported that GSK-3b
regulates the migration of radial glial cells, known as NSCs,
in developing cortices.68,69 Thus, the activation of GSK-3b by
Ab oligomers aberrantly regulates and reduces the migratory
potential of human NSCs.
Transplantation of human stem cells has the potential to be a
versatile therapy for various diseases. However, research on the
potential therapeutic use of stem cells for AD has lagged far
behind that of many other neurodegenerative disorders, because
the pathogenesis of AD remains uncertain. Herein, we demon-
strate that naturally secreted Ab oligomers regulate the pro-
liferation, differentiation and migration of human NSCs via the
GSK-3b signaling pathway. These findings will contribute to the
development of human NSC-based treatment for AD patients
by facilitating an increased understanding of the relationships
between the properties of NSCs and Ab oligomers.
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